CTOs on the Move

MIGUN USA CORPORATION

www.migunworld.com

 
MIGUN USA CORPORATION is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.migunworld.com
  • 3700 Wilshire Blvd Ste 820
    Los Angeles, CA USA 90010
  • Phone: 213.388.3300

Executives

Name Title Contact Details

Similar Companies

HydraFacial

BeautyHealth is a category-creating beauty health company focused on bringing innovative products to market. Our flagship brand, Hydrafacial, is a non-invasive and approachable beauty health platform and ecosystem with a powerful community of estheticians, consumers and partners, bridging medical and consumer retail to democratize and personalize skin care solutions for the masses. Leading the charge in beauty health as a category-creator, Hydrafacial uses a unique delivery system to cleanse, extract, and hydrate with their patented hydradermabrasion technology and super serums that are made with nourishing ingredients, providing an immediate outcome and creating an instantly gratifying glow in just three steps and 30 minutes. Hydrafacial® and Perk™ products are available in over 87 countries with over 19,000 Delivery Systems globally and millions of treatments performed each year. Hydrafacial is a wholly owned subsidiary of BeautyHealth. BeautyHealth`s shares trade on the Nasdaq Capital Market under the ticker symbol SKIN.

B and L Biotech

B and L Biotech is a Bala Cynwyd, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AADCO Medical Inc

AADCO Medical Inc is a Randolph, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EnteroMedics

EnteroMedics® Inc. is the developer of vBloc® neurometabolic therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. vBloc Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals. vBloc Therapy is now approved by the Food and Drug Administration for weight loss in adults with a BMI of 40 to 45 kg/m2 or a BMI of 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels.* *Individuals should have first tried to lose weight by diet and exercise in a supervised program within the last 5 years before receiving the Maestro System.

NeoVista

NeoVista Inc. is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.